Loading...
•
Jun 30, 2024
ADMA Biologics Q2 2024 Earnings Report
ADMA Biologics' Q2 2024 financial performance was marked by significant revenue and earnings growth, driven by increased sales of ASCENIV and a favorable product mix, leading to upwardly revised financial guidance for 2024 and 2025.
Key Takeaways
ADMA Biologics reported a strong second quarter in 2024, with a 78% increase in total revenue to $107.2 million and a net income of $32.1 million, driven by increased sales of ASCENIV and a favorable product mix. The company's adjusted EBITDA reached $44.5 million, and based on this performance, ADMA has increased its financial guidance for 2024 and 2025.
Total revenue for Q2 2024 reached $107.2 million, a 78% increase year-over-year.
GAAP net income for Q2 2024 was $32.1 million, a $38.4 million increase year-over-year.
Adjusted EBITDA for Q2 2024 was $44.5 million, representing a nearly 600% increase year-over-year.
The company increased its full-year 2024 revenue guidance to over $400 million and net income guidance to over $105 million.
Forward Guidance
ADMA Biologics has upwardly revised its financial guidance for FY 2024 and 2025. Total revenue is now expected to be more than $400 million and $445 million, respectively. Net income is projected to exceed $105 million and $155 million, respectively. Adjusted EBITDA is anticipated to surpass $150 million and $200 million, respectively.
Positive Outlook
- Total revenue is now expected to be more than $400 million and $445 million for FY 2024 and 2025, respectively.
- Net income is now expected to exceed $105 million and $155 million for FY 2024 and 2025, respectively.
- Adjusted EBITDA is now expected to exceed $150 million and $200 million for FY 2024 and 2025, respectively.
- Commercial-scale production of ADMA’s innovative biologics manufacturing process demonstrated a potential enhancement of yields by approximately 20% from the same starting plasma.
- The ongoing post-marketing pediatric clinical study for ASCENIV may provide label expansion opportunities.
Challenges Ahead
- Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...